Anthropic PBC rolled out a new life sciences effort and said Claude helped spot a novel enzyme system associated with certain DNA sequences, which the company said resembled Crispr. The group's goal is to deploy Claude to sift extremely large DNA databases and identify proteins that researchers can evaluate in laboratory experiments.
Anthropic laid out the work in a blog post and a companion technical paper that walks through how its AI agents ran the hunt on their own. The paper notes, "Many scientific discoveries originated when a scientist looked closely at the data and recognized something unusual as worth pursuing," and, "Here, these steps were taken by AI agents working together without human supervision."
In an email, Eric Kauderer-Abrams, who leads life sciences at Anthropic, said researchers "don't yet know" how significant the enzyme system will be. He added, "The report that we shared this week is as much about how the research was performed as it is about the content of the underlying discovery itself," and, "We plan to follow up with in-depth experiments trying to understand its function and potential relevance as a tool." The write-up is available on Anthropic's site along with a technical paper, but no peer reviewed journal has published it.
Plenty of experts like the idea of using AI here but balked at the framing. On X, Lucas Harrington, a biotech entrepreneur and scientist who has cofounded multiple gene editing companies, wrote: "Announcing these very early, incremental findings with the framing of a major discovery doesn't help," and, "The hard part, and where the real discoveries come from, is figuring out what the system actually does." Eli Lilly & Co. CEO Dave Ricks replied to that post, calling it the "Best summary of this finding and the concerns expressed by many about the way this has been framed and disclosed…"
Steven Salzberg, who directs Johns Hopkins University's Center for Computational Biology, said there are already many tools to find Crispr-like enzymes and that similar enzymes have been uncovered over the years. "What most biologists don't do is to announce an unproven, preliminary finding as if it's the next Crispr, suggesting that they have something revolutionary," he said. "That's the behavior of a profit-seeking, attention-seeking company, not a scientist." Philip Kranzusch, a biochemist at Harvard Medical School, called it "a really exciting beginning observation," while adding, "It is not what we would describe as a breakthrough in biology." Others highlighted the promise of mining bacterial and viral genomes with AI, noting the datasets are enormous and expanding fast, but said the scientific meaning here is still unclear.
New technologies change how innovation unfolds, so steady strategies protect your financial future. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.
Investors reacted quickly: after the announcement, shares of Crispr Therapeutics AG and Editas Medicine Inc. fell. Anthropic pitched the result as a proof point that AI can sift giant databases of genetic code and surface interesting biology, potentially laying groundwork for new medical tools. Drugmakers are chasing the same goal to boost the low success rate of turning ideas into medicines, a push that historically ran through biotech startups working with larger pharma partners.
Big players are stepping in more directly. In January, Nvidia Corp. announced it would commit $1 billion across five years to a new laboratory with Eli Lilly, with the aim of accelerating AI within the pharmaceutical industry. Earlier this month, Novo Nordisk A/S announced a partnership with Anthropic to hasten drug development. Anthropic's reveal also came weeks after OpenAI claimed it had solved the Navier-Stokes Millennium Prize Problem, a claim that drew similar skepticism from mathematicians who said it did little to deepen understanding of fluid mechanics.
Anthropic has been adding biology talent. In June it hired Nobel Laureate John Jumper from Google DeepMind, who shared in a prize for creating AlphaFold. The lead author on this week's work is Peter H. Yoon, formerly a researcher in UC Berkeley biochemist Jennifer Doudna's lab.
Doudna shared the Nobel Prize for Crispr. Anthropic says its next step is hands-on experiments to figure out what the newly flagged system does and whether it could become a useful tool.
This is your reminder that early-stage science can jolt stock prices even when the story is just getting started. Here, the write-up isn't peer reviewed, Anthropic says its researchers "don't yet know" the finding's significance, and outside experts are counseling caution. When headlines tie AI and biology to market moves, the real verdict usually arrives in the lab later, not on announcement day.
Curiosity about breakthroughs reminds investors to balance opportunity with careful preservation of capital. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.
